Revenue in Q4 2023 increased 28%. New Products (i) revenue grew by $2.19 billion to $2.49 billion in Q4 2023, led by Mounjaro and Zepbound. Growth Products (ii) revenue increased 9% to $5.27 billion in Q4 2023, led by Verzenio and Jardiance. Pipeline progress included  FDA approval of Zepbound for

INDIANAPOLIS , Jan. 23, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2023 financial results and 2024 financial guidance on Feb. 6, 2024 . Lilly will also conduct a conference call that day with the investment community and media to further detail the

INDIANAPOLIS , Jan. 2, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the 42nd Annual J.P. Morgan Healthcare Conference , Jan. 8-11, 2024 . David A. Ricks, Lilly 's chair and CEO, will participate in a fireside chat on Jan. 9 at 5:15 p.m. Eastern time .

INDIANAPOLIS , Dec. 8, 2023 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has announced a 15% increase in its quarterly dividend and declared a dividend for the first quarter of 2024 of $1.30 per share on outstanding common stock.

INDIANAPOLIS , Nov. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the sixth annual Evercore ISI HealthCONx Conference on Nov. 28, 2023 . Daniel Skovronsky, M.D., Ph.D., executive vice president, chief scientific and medical officer, and president of Lilly Research

Revenue in Q3 2023 increased 37%, driven by growth from Mounjaro, Verzenio and Jardiance, as well as $1.42 billion from the sale of rights for the olanzapine portfolio (Zyprexa). Excluding revenue from the olanzapine portfolio and COVID-19 antibodies, revenue in Q3 2023 increased 24%.

INDIANAPOLIS , Nov. 1, 2023 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2023 of $1.13 per share on outstanding common stock. The dividend is payable on Dec. 8, 2023 to shareholders of record at the close of business

INDIANAPOLIS , Oct. 26, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the UBS Biopharma Conference on Nov. 8, 2023 . Patrik Jonsson, executive vice president; president, Lilly Immunology; president, Lilly USA ; and chief customer officer, will participate in a fireside chat at

INDIANAPOLIS , Oct. 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2023 financial results on Thursday, Nov. 2, 2023 . Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial

INDIANAPOLIS , Aug. 29, 2023  /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley 21st Annual Global Healthcare Conference, Sept. 11-12, 2023 . Daniel Skovronsky, M.D., Ph.D., executive vice president, chief scientific and medical officer, and president of Lilly